Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by cytochromeon May 09, 2016 3:29pm
115 Views
Post# 24855133

RE:RE:RE:RE:RE:RE:RE:Sorry about that last one !

RE:RE:RE:RE:RE:RE:RE:Sorry about that last one !I hate to keep beating you over the head Bencro....I've never said TLC is crappy. It's just not superior to many other devices and is not at all the revolutionary pain relief device you and your Dr. Google buddies boast about. Hence, sales will not be sky high because it's the same old same old as TLC 1000, just double the power. And please don't spew double the power means double the results BS. Look up the dose response papers to understand why. By definition, LLLT has to be under 500 mW per diode so anything under that is athermal and will give results. Wonder why the third L in LLLT has been changed from Laser to Light? Cause the source of the light isn't always critical to results. LEDs and broadband light can also be used for LLLT -  not just lasers. Of course, lasers provide energy deeper to tissues to a maximum depth.

Red light barely penetrates the epidermis so is really only useful for superficial conditions and irradidating the blood contained in the suprefiical tissues. 

BTW, I read all 3 of those papers and this statement does NOT appear in any of the papers. Your quote is from TLT and not the research:

Experimental data clearly supports the use of 660 nm and 905 nm laser light as the best choices

And my point which you just can't seem to comprehend, is that action spectra of CCO has several peaks, 904/5 is NOT one of them. According to Karu (please research her and learn a little), the range of peaks are: 620-680, 760-830 with well pronounced maxima at 620, 680, 760 and 820 nm. So what soes this mean? It means, light that is absorbed in these wavelengths will stimulate CCO optimally - thereby maximizing LLLT effects. Of course, 904/5nm will also stimulate CCO, but too a lesser degree. Why Bencro? Cause, photospectroscopy doesn't lie and the action spectra has been scientifcally researched and stated for all to see and understand.


  

Bullboard Posts